This week, researchers announced that they've potentially found a way to use nanoparticles to help decrease the risk of a second heart attack or stroke. By creating a synthetic version of a high-density lipoprotein, researchers are able to use nanoparticles as a vehicle to transport molecules that would normally be harder to move inside the body.
Scientists from the Icahn School of Medicine at Mount Sinai published a study in the journal Nature Communications that shows that an HDL nanoparticle loaded with cholesterol-lowering statins could target and reduce inflammation in blood vessels. Often, after a heart attack, such levels have been known to cause a second heart attack or stroke due to a ruptured clot. The nanoparticle the team used resembles the "good" HDL cholesterol particle and binds to the same receptors as the natural version to deliver the statin drug, according to a report from Mount Sinai. Oral statins work through the liver to reduce "bad" LDL cholesterol levels and have a small effect on inflammatory cells in the arteries.
This study helped decrease inflammation when tested on mice, something that has always been a big risk factor after a heart attack. How could this new method help to advance other types of cardiovascular treatment?
Want to learn more about the future of drug delivery? IIR's 18th Annual Drug Delivery Partnerships will help you form a drug delivery strategy that keeps you ahead of the market, register today! Save 15% off of the standard rate when you register using priority code XP1978BLOG. To learn more, download our agenda. We hope to see you January 27-29 in Boca Raton!